Lorcainide

Lorcainide
Clinical data
ATC code
Pharmacokinetic data
Protein binding78
Elimination half-life14.3 +/-3.7
Identifiers
  • N-(4-chlorophenyl)-N-(1-isopropylpiperidin-4-yl)-2-phenylacetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27ClN2O
Molar mass370.92 g·mol−1
3D model (JSmol)
  • Clc3ccc(N(C(=O)Cc1ccccc1)C2CCN(C(C)C)CC2)cc3
  • InChI=1S/C22H27ClN2O/c1-17(2)24-14-12-21(13-15-24)25(20-10-8-19(23)9-11-20)22(26)16-18-6-4-3-5-7-18/h3-11,17,21H,12-16H2,1-2H3 checkY
  • Key:XHOJAWVAWFHGHL-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Lorcainide (Lorcainide hydrochloride) is a Class 1c antiarrhythmic agent that is used to help restore normal heart rhythm and conduction in patients with premature ventricular contractions, ventricular tachycardiac[1] and Wolff–Parkinson–White syndrome.[2] Lorcainide was developed by Janssen Pharmaceutica (Belgium) in 1968 under the commercial name Remivox and is designated by code numbers R-15889 or Ro 13-1042/001.[3] It has a half-life of 8.9 +- 2.3 hrs which may be prolonged to 66 hrs in people with cardiac disease.[2]

  1. ^ Cite error: The named reference Samánek_1987 was invoked but never defined (see the help page).
  2. ^ a b Cite error: The named reference Winkle_1984 was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference Amery_1983 was invoked but never defined (see the help page).